The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer

M. Adams, H. Navabi, D. Croston, S. Coleman, Z. Tabi, A. Clayton, B. Jasani, M. D. Mason

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.

Original languageEnglish
Pages (from-to)2374-2378
Number of pages5
JournalVaccine
Volume23
Issue number17-18
DOIs
Publication statusPublished - Mar 18 2005
Externally publishedYes

Fingerprint

Toll-Like Receptor 3
exosomes
Exosomes
ovarian neoplasms
immunotherapy
Neoplasm Antigens
Ovarian Neoplasms
Immunotherapy
agonists
T-Lymphocytes
neoplasms
Drug Therapy
Neoplasms
T-lymphocytes
antigens
Immunosuppression
drug therapy
Clinical Trials
Recurrence
Survival

Keywords

  • Ovarian cancer
  • TLR3
  • Tumour-derived exosomes
  • Tumour-specific T cells

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. / Adams, M.; Navabi, H.; Croston, D.; Coleman, S.; Tabi, Z.; Clayton, A.; Jasani, B.; Mason, M. D.

In: Vaccine, Vol. 23, No. 17-18, 18.03.2005, p. 2374-2378.

Research output: Contribution to journalArticle

Adams, M, Navabi, H, Croston, D, Coleman, S, Tabi, Z, Clayton, A, Jasani, B & Mason, MD 2005, 'The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer', Vaccine, vol. 23, no. 17-18, pp. 2374-2378. https://doi.org/10.1016/j.vaccine.2005.01.014
Adams, M. ; Navabi, H. ; Croston, D. ; Coleman, S. ; Tabi, Z. ; Clayton, A. ; Jasani, B. ; Mason, M. D. / The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. In: Vaccine. 2005 ; Vol. 23, No. 17-18. pp. 2374-2378.
@article{f0afa88468064c03be6422cd1facd54a,
title = "The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer",
abstract = "A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.",
keywords = "Ovarian cancer, TLR3, Tumour-derived exosomes, Tumour-specific T cells",
author = "M. Adams and H. Navabi and D. Croston and S. Coleman and Z. Tabi and A. Clayton and B. Jasani and Mason, {M. D.}",
year = "2005",
month = "3",
day = "18",
doi = "10.1016/j.vaccine.2005.01.014",
language = "English",
volume = "23",
pages = "2374--2378",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier",
number = "17-18",

}

TY - JOUR

T1 - The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer

AU - Adams, M.

AU - Navabi, H.

AU - Croston, D.

AU - Coleman, S.

AU - Tabi, Z.

AU - Clayton, A.

AU - Jasani, B.

AU - Mason, M. D.

PY - 2005/3/18

Y1 - 2005/3/18

N2 - A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.

AB - A clinical trial employing an immunotherapeutic approach based on the use of a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes carrying tumour-associated antigens is planned in advanced ovarian cancer in conjunction with conventional first line chemotherapy. Most patients with ovarian cancer present with advanced disease and despite high initial response rate to chemotherapy the majority will relapse within 2 years with poor overall survival. Tumour antigen-specific T cells are naturally occurring in ovarian cancer patients and T cell infiltration of the tumour is highly prognostic. Novel immunotherapy to expand and activate tumour antigen-specific T cells combined with adjuvant treatment to overcome tumour-induced immunosuppression is considered to be therapeutically beneficial. The rationale for adopting such a combined approach is discussed here.

KW - Ovarian cancer

KW - TLR3

KW - Tumour-derived exosomes

KW - Tumour-specific T cells

UR - http://www.scopus.com/inward/record.url?scp=14844303287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844303287&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.01.014

DO - 10.1016/j.vaccine.2005.01.014

M3 - Article

VL - 23

SP - 2374

EP - 2378

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 17-18

ER -